Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Ameet Mallik
|
| gptkbp:country |
gptkb:Switzerland
|
| gptkbp:focus |
oncology
|
| gptkbp:foundedYear |
2011
|
| gptkbp:founder |
gptkb:Chris_Martin
|
| gptkbp:fullName |
ADC Therapeutics
|
| gptkbp:headquartersLocation |
gptkb:Lausanne,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
ADCT
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:product |
Zynlonta
camidanlumab tesirine |
| gptkbp:specialty |
antibody-drug conjugates
|
| gptkbp:stockExchange |
gptkb:NYSE
|
| gptkbp:stockSymbol |
gptkb:ADCT
|
| gptkbp:website |
https://adctherapeutics.com
|
| gptkbp:bfsParent |
gptkb:ADC_Telecommunications
|
| gptkbp:bfsLayer |
7
|